EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured)

Nadia Noormohamed, Tamara Lukic, Thomas C Marbury, Eric J Lawitz, Holly Prescott, Mindy Magee, Ahmed Nader, Kelong Han

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1454 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Nadia Noormohamed und 7 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Healthy Volunteers, Area Under Curve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bepirovirsen is a developmental antisense oligonucleotide (ASO) for treatment of chronic hepatitis B virus infection. No pharmacokinetic (PK) studies comparing participants with hepatic impairment (HI) and healthy participants (HPs) have been conducted with ASOs. Given the target patient population, characterization of bepirovirsen PK in HI was imperative. This phase 1, nonrandomized, open‐label study (NCT04971928) evaluated the PKs of a single 300‐mg dose of bepirovirsen in participants with HI and matched HPs, enrolled in 2 parts (Part 1: moderate HI; Part 2: mild HI). If no predefined difference in the area under the concentration‐time curve from time 0 (predose) to infinite time (AUC 0‐∞ ) and maximum observed concentration (C max ; geometric mean ratio [GMR] 0.5‐1.5) was identified in Part 1, findings were applied to mild HI, eliminating Part 2. Participants were monitored for 50 days post‐treatment and noncompartmental analysis estimated PK parameters. Twenty‐four participants (moderate HI, n = 12; HP, n = 12) received bepirovirsen and completed Part 1. AUC 0‐∞ and C max were lower in participants with moderate HI (GMR 0.69 and 0.67, respectively) than in HPs, while apparent clearance (CL/F) and apparent terminal phase volume of distribution (Vz/F) were higher (GMR 1.44 and 1.64, respectively), but fell within the predefined thresholds of difference for this study. Part 2 was omitted. Adverse events were mild. Moderate HI did not have a clinically relevant impact on bepirovirsen PK or safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHealthy VolunteersArea Under CurveHumansMaleFemaleAdultMiddle AgedYoung AdultHepatitis B, ChronicAgedLiver Diseases

Stichwörter der Autor:innen

antisense oligonucleotidebepirovirsenhepatic impairmenthepatitis Bpharmacokinetics

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • GSK, Collegeville, USA.
  • GSK, Dubai, UAE.
  • Orlando Clinical Research Center, Orlando, USA.
  • Texas Liver Institute, UT Health San Antonio, San Antonio, USA.
  • Plus-Project Ltd, Knutsford, UK.

Zitieren

APA

Noormohamed, N., Lukic, T., Marbury, T. C., Lawitz, E. J., Prescott, H., Magee, M., Nader, A., & Han, K. (2024). A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured). Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1454

Vancouver

Noormohamed N, Lukic T, Marbury TC, Lawitz EJ, Prescott H, Magee M, et al. A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured). Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1454

BibTeX
@article{Noormohamed2024,
  author = {Noormohamed, Nadia and Lukic, Tamara and Marbury, Thomas C and Lawitz, Eric J and Prescott, Holly and Magee, Mindy and Nader, Ahmed and Han, Kelong},
  title = {A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured)},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1454}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche